Reported Friday, MannKind’s Under-10-Second Furoscix ReadyFlow Autoinjector Shows Urine Output Comparable To IV Furosemide In New HFSA 2026 Analyses, Supporting Outpatient Edema Management In Heart Failure And CKD

MannKind's Furoscix ReadyFlow autoinjector has demonstrated urine output comparable to IV furosemide, supporting its use in outpatient management of heart failure and chronic kidney disease (CKD). The analyses show consistent bioavailability and diuretic responses, facilitating flexible administration in clinical settings. These findings build on the FDA approval and U.S. launch of Furoscix ReadyFlow in July 2026, marking it as the first autoinjector for IV-equivalent diuretic therapy.